CLINICAL TRIALS
Ozempic in Diabetics with CKD: Fewer Cardiac Deaths and Slower Progression
In diabetics with chronic kidney disease, semaglutide has shown reductions in cardiac deaths and delayed CKD progression. What to monitor.
Dr. James Wilson
November 3, 2025
6 min read
Ozempic in Diabetics with CKD: Fewer Cardiac Deaths and Slower Progression
Clinical data in type 2 diabetes with chronic kidney disease associate semaglutide (Ozempic) with fewer cardiac deaths and slower CKD progression.
Key Clinical Signals
- Cardiovascular: Lower cardiac death events vs control cohorts.
- Renal: Slower eGFR decline and fewer progression events in studied populations.
Clinical Application
- Optimize RAAS blockade and SGLT2 where indicated; GLP-1s are complementary.
- Track BP, A1C, eGFR, albuminuria, and body weight.
- Manage GI tolerability during dose escalation.
- Cardiovascular: Lower cardiac death events vs control cohorts.
- Renal: Slower eGFR decline and fewer progression events in studied populations.
Clinical Application
- Optimize RAAS blockade and SGLT2 where indicated; GLP-1s are complementary.
- Track BP, A1C, eGFR, albuminuria, and body weight.
- Manage GI tolerability during dose escalation.
About Dr. James Wilson
Regenerative medicine researcher and anti-aging specialist focusing on peptide-based therapies.
CardiometabolicNephrologyPeptide Research
Related Articles
NEWS
Navigating the GLP-1 Gray Market: Access, Affordability, and Safety in 2025
High demand and limited coverage have pushed some to gray-market GLP-1s. Learn the risks, legal context, safer access routes, and cost strategies.
Dr. Sarah Chen
Nov 3, 2025
8 min read
GLP-1 medicationsgray marketOzempic+3 more
CLINICAL TRIALS
How GLP-1 Medications Are Reshaping Consumer Behavior and Markets
From grocery baskets to wellness spend, GLP-1s are changing consumer habits. What brands and patients should know.
Dr. James Wilson
Nov 3, 2025
7 min read
GLP-1 medicationsconsumer behaviormarket trends+2 more
WEIGHT LOSS
GLP-1 Receptor Agonists and Alcohol: What Early Studies Show in Obesity
Preliminary data suggest GLP-1 RAs may alter alcohol’s physiological and perceptual effects in people with obesity. What to know and discuss with your clinician.
Dr. Sarah Chen
Nov 3, 2025
6 min read
GLP-1 receptor agonistsalcohol consumptionobesity+1 more